{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| IUPAC_name = ''9-chloro-6-(2-fluorophenyl)-4-hydroxy''<br />''-2-(2-hydroxyethyl)-2,5-diazabicyclo''<br />''[5.4.0]undeca-5,8,10,12-tetraen-3-one''
| image = Doxefazepam.svg
| image2 = Doxefazepam3d.png

<!--Clinical data-->
| tradename =  
| pregnancy_category =
| legal_CA= Schedule IV
| legal_US = Schedule IV
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 3-4 hours<ref>http://www.intox.org/databank/documents/pharm/doxefzpm/iarc796.htm</ref>
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 40762-15-0
| ATC_prefix = N05
| ATC_suffix = CD12
| PubChem = 38668
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 35431
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 231RV72C8L verifiedrevid = 457288969
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07327
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 64677

<!--Chemical data-->
| C=17 | H=14 | Cl=1 | F=1 | N=2 | O=3 
| molecular_weight = 348.8
| smiles = FC1=CC=CC=C1C2=NC(C(N(CCO)C3=C2C=C(C=C3)Cl)=O)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H14ClFN2O3/c18-10-5-6-14-12(9-10)15(11-3-1-2-4-13(11)19)20-16(23)17(24)21(14)7-8-22/h1-6,9,16,22-23H,7-8H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VOJLELRQLPENHL-UHFFFAOYSA-N
}}

'''Doxefazepam''' (marketed under brand name '''Doxans''') is a [[benzodiazepine]] derivative drug developed by Schiapparelli in the 1970s.<ref>DE Patent 2338058 - BENZODIAZEPINVERBINDUNGEN FUER DIE THERAPIE</ref> It possesses [[anxiolytic]], [[anticonvulsant]], [[sedative]] and [[skeletal muscle relaxant]] properties. It is used therapeutically as a [[hypnotic]].<ref>{{cite journal |pmid=6483162 |year=1984 |last1=Rodriguez |first1=G |last2=Rosadini |last3=Sannita |last4=Strumia |title=Effects of doxefazepam on normal sleep. An EEG and neuropsychological study |volume=11 |issue=2 |pages=133–9 |journal=Neuropsychobiology |first2=G |first3=WG |first4=E |doi=10.1159/000118066}}</ref> According to Babbini and colleagues in 1975, this derivative of [[flurazepam]] was between 2 and 4 times more potent than the latter while at the same time being half as toxic in laboratory animals.<ref name=SAS_643_1975>{{cite journal | vauthors=Babbini M, Torrielli MV, Strumia E, Gaiardi M, Bartoletti M, De Marchi F  |date=August 1975 | title = Sedative-hypnotic properties of a new benzodiazepine in comparison with flurazepam. Pharmacological and clinical findings | journal = Arzneimittel-Forschung | volume = 25 | issue = 8 | pages = 1294–1300 | pmid = 241364 }}</ref> Section 5.5 of the article ''Doxefazepam'' in volume 66 of the [[World Health Organization|World Health Organization's]] (WHO) and [[International Agency for Research on Cancer|International Agency for Research on Cancer's]] (IARC) ''IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans'', an article describing the carcinogenic/toxic effects of doxefazepam on humans and experimental animals, states that there is "inadequate evidence in humans for the [[carcinogen]]icity of doxefazepam" and limited evidence in experimental for the carcinogenicity of doxefazepam," and concluded that the overall evaluation of the substance's carcinogenicity to humans is "not classifiable."<ref>{{cite journal |date=13–20 Feb 1996 |title=Doxefazepam |url=http://monographs.iarc.fr/ENG/Monographs/vol66/mono66-7.pdf |journal=IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans |publisher=International Agency For Research On Cancer (IARC) |volume=66 |pages=97–104 |accessdate=10 July 2014}}</ref>

==See also==
*[[Benzodiazepine]]

==References==
{{reflist}}

==External links==
* [http://www.inchem.org/documents/pims/pharm/pim924.htm Inchem.org - Doxefazepam]
* [http://monographs.iarc.fr/ENG/Monographs/vol66/mono66-7.pdf IARC Monographs - Doxefazepam]

{{Benzodiazepines}}
{{Hypnotics and sedatives}}
{{GABAAR PAMs}}

[[Category:Alcohols]]
[[Category:Benzodiazepines]]
[[Category:Chloroarenes]]
[[Category:Fluoroarenes]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Hypnotics]]
[[Category:Lactams]]

{{sedative-stub}}